Radnostix, Inc. (Formerly International Isotopes Inc.) Announces Mutual Termination of Major Asset Purchase Agreement and Details Voluntary Product Recall

Key Points of the Report

• Termination of \$12.6 Million Asset Purchase Agreement (APA) with American Fuel Resources, LLC (AFR)
• Voluntary recall of specific lots of Dibasic Sodium Phosphate Capsules, with estimated financial impacts disclosed
• Potential implications for shareholders, including reversal of previously anticipated liquidity event and strategic asset review

1. Termination of Material Asset Purchase Agreement

On March 16, 2026, Radnostix, Inc. (NASDAQ: RNX), previously known as International Isotopes Inc., announced the mutual termination of its Asset Purchase Agreement (APA) with American Fuel Resources, LLC (AFR). The APA, originally executed on February 8, 2024, involved the sale of Radnostix’s depleted uranium deconversion and fluorine extraction plant (the “DUF6 Plant”) and related assets for a total consideration of \$12,620,000. This included a non-refundable \$50,000 prepayment, \$120,000 in NRC extension fees, and a \$12,450,000 payment due at closing.

The termination arose after AFR requested a 1-year extension because it could not make the remaining payment by the March 31, 2026 deadline. Although both parties were in the final stages of securing U.S. Nuclear Regulatory Commission (NRC) consent for the transfer, they mutually agreed to withdraw their regulatory application and end the APA.

Shareholder Impact and Price-Sensitive Matters

• Reversal of Anticipated Proceeds and Gain: The company will not receive the \$12.45 million payment, nor will it recognize an associated gain on the sale of assets. Previously disclosed plans to use these proceeds to repay long-term debt and improve liquidity and financial flexibility are now void.
• Strategic Control of Appreciated Assets: Management determined that regaining control of the DUF6 Plant and related assets was in the best interest of shareholders, especially as market conditions for uranium conversion facilities have improved. The company cited “low confidence” in AFR’s ability to secure necessary funding as a reason for termination. Radnostix believes the DUF6 assets have appreciated in value since the original agreement and plans to evaluate all possible options for monetizing or utilizing these assets.

What Shareholders Need to Know

• This is a significant development, as the APA represented a major liquidity event and strategic transaction for Radnostix. The failure to close the deal means the company’s balance sheet, cash flow, and debt repayment plans will remain as previously reported, without the expected boost from the asset sale.
• There is potential upside if Radnostix can realize greater value from the DUF6 Plant in the current market environment, but this is subject to strategic review and market risks.
• Radnostix will continue to own and control the DUF6 Plant and related licenses, patents, and agreements, with management exploring alternative paths forward.

2. Voluntary Recall of Pharmaceutical Component and Financial Implications

On February 19, 2026, during an internal quality audit, Radnostix discovered that certain lots of Dibasic Sodium Phosphate Capsules, provided with its Generic Sodium Iodide I-131 diagnostic kits manufactured between 2022 and 2025, may be out of specification due to final capsule weight. The company initiated a voluntary recall of impacted lots shipped between August 19, 2024, and February 17, 2026. All affected pharmacies, clinics, and veterinarians have been notified, and the U.S. Food and Drug Administration (FDA) is aware of the action.

Financial and Operational Impact

• Q4 2025 One-time Charge: Approximately \$75,000 for inventory write-off related to the recall.
• Q1 2026 One-time Charge: Approximately \$50,000 for customer refunds.
• Additional 2026 Costs: Expected to be around \$75,000 for new capsule inventory, plus an estimated \$25,000 to \$75,000 per week in lost revenue, depending on recall duration.
• Radnostix does not anticipate the recall will materially impact its ability to provide Sodium Iodide I-131 or its partners’ ability to service patients. The company expects the recall’s impact will not extend beyond the second quarter of 2026.

Shareholder Impact and Price Sensitivity

• This recall, while not currently deemed “material” under SEC disclosure thresholds, could affect short-term financial results and revenue. Investors should monitor upcoming quarterly filings for updated impact assessments.
• Importantly, the company asserts that the recall does not affect the main Generic Sodium Iodide I-131 product, which remains available and unaffected.

3. Forward-Looking Statements and Risk Factors

Management highlights that all forward-looking statements regarding the financial impact of the APA termination, the recall, and the future value of the DUF6 Plant are subject to significant risks and uncertainties. These include the ability to monetize assets, costs associated with the recall, potential impacts on cash flow, and other risks as described in Radnostix’s filings with the Securities and Exchange Commission.

Conclusion

The mutual termination of the DUF6 Plant APA and the voluntary recall of a component in a key diagnostic kit are both material events for Radnostix, Inc. Shareholders should closely watch management’s next steps regarding the valuable DUF6 asset and monitor for additional disclosures regarding the financial and market impact of the product recall. These events have the potential to significantly influence the company’s near- and mid-term financial performance, strategic direction, and ultimately, share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Forward-looking statements are subject to risks and uncertainties. Readers should refer to official filings with the Securities and Exchange Commission for full details and risk disclosures.

View INTERNATIONAL ISOTOPES INC Historical chart here